<DOC>
	<DOCNO>NCT01473030</DOCNO>
	<brief_summary>The overall goal project quantify long-term effect dutasteride architectural nuclear feature benign prostate tissue , use state-of-the art digital image analysis technique . The ultimate result multivariable morphological `` signature '' could provide useful indicator individual 's degree drug response .</brief_summary>
	<brief_title>Long-term Effects Dutasteride Architectural Nuclear Morphometric Features Benign Prostate Tissue</brief_title>
	<detailed_description />
	<mesh_term>Dutasteride</mesh_term>
	<criteria>complete REDUCE trial ( Year 4 exit biopsy block HE slide available ; i.e. , U.S. participant ) compliant assign treatment base either : ( dutasteride group ) least 3 postbaseline serum DHT level ≥ 50 % low baseline , ( placebo group ) least 3 postbaseline serum DHT level none show ≥ 50 % decrease baseline subgroup : Year 2 biopsy block HE slide available Aim 4a</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Benign prostate</keyword>
	<keyword>serum DHT</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>PSA</keyword>
	<keyword>Avodart</keyword>
</DOC>